Young smiling boy
gray picture on left of breadcrumbs
 > Home  > Medical  > conclusions  > uvwxyz

References: U, V, W, X, Y, Z

  • Uhari, M., T. Kontiokari, and M. Niemela. 1998. A novel use of xylitol sugar in preventing acute otitis media [see comments]. Pediatrics 102:879-884.
  • Vanden Borre, R., R. Vermote, M. Buttiens, P. Thiry, G. Dierick, J. Geutjens, G. Sieben, and S. Heylen. 1993. Risperidone as an add-on therapy in behavioural disturbances in mental retardation: A double-blind placebo-controlled cross-over study. Acta Psychiatr. Scand. 83:167-171.
  • von Gontard, A. 1998. Annotation: Day and night wetting in children--a paediatric and child psychiatric perspective [see comments]. J. Child Psychol. Psychiatry 39:439-451.
  • Wang, J., and R. W. Erbe. 1984. Folate metabolism in cells from fragile X syndrome patients and carriers. Am. J. Med. Genet. 17:303-310.
  • Warnock, J. K., and T. Kestenbaum. 1992. Pharmacologic treatment of severe skin-picking behaviors in Prader-Willi syndrome. Arch. Dermatol. 128:1623-1625.
  • Weiger, W. A., and D. M. Bear. 1988. An approach to the neurology of aggression. J. Psychiatr. Res. 22:85-98.
  • Wiegers, A. M., L. M. Curfs, E. L. Vermeer, and J. P. Fryns, 1993. Adaptive behavior in the fragile X syndrome: profile and development. Am. J. Med. Genet. 47:216-20.
  • Wilens, T. E. 1999. Straight talk about psychiatric medications for kids. New York: Guilford Press.
  • Wilens, T. E., J. Biederman, and T. Spencer. 1994. Clonidine for sleep disturbances associated with attention deficit hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 33:424-426.
  • Wilens, T. E., T. Spencer, J. Biederman, J. Wozmak, and D. Connor. 1995. Combined pharmacotherapy: An emerging trend in pediatric psychopharmacology. J. Am. Acad. Child Adolesc. Psychiatry 34:110-112.
  • Wilens, T. E., D. Wyatt, and T. J. Spencer. 1998. Disentangling disinhibition. J. Am. Acad. Child Adolesc. Psychiatry 37:1225-1227.
  • Wilens, T. E., T. J. Spencer, J. M. Swanson, D. F. Connor, and D. Cantwell. 1999. Combining methylphenidate and clonidine: A clinically sound medication option [see comments]. J. Am. Acad. Child Adolesc. Psychiatry 38:614-619; discussion 619-622.
  • Wilson, P., T. Stackhouse, R. O'Connor, S. Scharfenaker, and R. Hagerman. 1994. Issues and strategies for educating children with fragile X syndrome: A monograph. Dillon, Colo.: Spectra Publishing Company.
  • Wisniewski, K. E., S. M. Segan, C. M. Miezejeski, E. A. Sersen, and R. D. Rudelli. 1991. The fragile X syndrome: Neurological, electrophysiological, and neuropathological abnormalities. Am. J. Med. Genet. 38:476-480.
  • Woolston, J. L. 1999. Combined pharmacotherapy: Pitfalls of treatment. J. Am. Acad. Child Adolesc. Psychiatry 38:1455-1457.
  • Wright-Talamante, C., A. Cheema, J. E. Riddle, D. W. Luckey, A. K. Taylor, and R. J. Hagerman. 1996. A controlled study of longitudinal IQ changes in females and males with fragile X syndrome. Am. J. Med. Genet. 64:350-355.
  • Zettner, A., G. Boss, and J. E. Seegmiller. 1981. A long-term study of the absorption of large doses of folic acid. Ann. Clin. Lab. Sci. 11:517-524.
  • Zuddas, A., A. Di Martino, P. Muglia, and C. Cianchetti. 2000. Long term risperidone for pervasive developmental disorder: Efficacy, tolerability, and discontinuation. J. Child Adolesc. Psychopharmacol. 10:79-90.
     

This article is not intended to give medical advice for individual cases.  Any change in medical treatment should be done in consultation with appropriate medical personnel. This article is written for medical professionals.  Some of the terms will be unfamiliar to those who are not trained in medical fields.

*This article is from the chapter on treatment in the 3rd edition of Fragile X Syndrome: Diagnosis, Treatment, and Research edited by Randi Jenssen Hagerman, M.D. and Paul Hagerman, M.D., Ph.D., to be published May 2002.  It is included with permission from The Johns Hopkins University Press. References to other chapters refer to chapters in the book which are not included as part of this website.

The complete 3rd edition of Fragile X Syndrome: Diagnosis, Treatment, and Research can be ordered from the National Fragile X Foundation by calling 1-800-688-8765 or from The Johns Hopkins University Press at 1-800-537-5487.

Medical Follow-up   Pharmacotherapy   Future Prospects
Outline   Medications   Medical Conditions
References: A, B, C, D, EF, G, H, IJ, K, L, M, NOP, QR, S, T, UVWXYZ
 
back to homehow to navigatesite map creditsprivacycontact usdisclaimer

© copyright 1998-2008 NFXF
 
Medication can be important in the treatment of fragile X related behavior problems
TELL A FRIEND